CUV - banter and discussion, page-43

Rainy day so I've put a couple of numbers together to show why I believe strongly in Clinuvel and the growth they have to come now they have the US rollout underway. Whenever I do this I try to be as conservative as possible with my guesstimations. US potential revenue:

7 Treatment centres (multiplied by)
1 Patient per day receiving an implant (multiplied by)
5 Days per week (multiplied by)
4 Weeks per month

Equals 140 implants per month multiplied by $20000 AUD per implant equals $2,800,000 revenue per month or about $34 million a year.
This equates to just 40 patients per treatment centre (280 total in US) receiving 6 implants per year. This all seems very conservative to me but shows the massive potential just on EPP for Clinuvel. What about when 10, 15 or 20 centres are in operation? What if the price per implant is $28000 or $38000? We just don't know all the details but it can be seen how 6 over 4 implants will quickly put US sales in excess of EU sales. Some centres may do much better than this (eg southern, warmer centres) and some may do less, but I also guess more centres will open over the coming year so overall the 2020-21 financial year should be a bumper year for CUV. Then the other positives which will also add much value and we should see some progress on in the remainder of this calendar year.

* TGA application/approval
* Vitiligo trial and path to market
* France
* China
* Shorts continue to buyback shares and close their positions - with a potential 'squeeze' if new large buyers enter the market and compete for shares. Looking good here. All IMO, DYOR and GLTAH.